Two stocks in Healthcare
Oxford Biomedica vs Smith & Nephew: profit, growth, debt and price compared
Smith & Nephew is stronger on 4 of 6 figures: profit margin, debt, price for its expected profit and price trend. Oxford Biomedica is stronger on 2: sales growth and analysts' view.
Save both stocks to your watchlist and revisit their latest fundamentals.
| Oxford BiomedicaOXB.L | Smith & NephewSN.L | |
|---|---|---|
| Net margin | −23.2% | Stronger: 10.1% |
| Revenue growth, past year | Stronger: +9.00% | +4.60% |
| Debt to equity | 273.1% | Stronger: 73.1% |
| Forward P/E | Loss | Stronger: 13.2× |
| Dividend yield | — | 2.55% |
| Analysts | Stronger: Buy · 8 | Hold · 17 |
| From its 200-day average | −5.2% | Stronger: +1.4% |
Share price over the past year
- Oxford Biomedica−13.2%
- Smith & Nephew−6.8%
20 Nov 202518 Nov 2026
Oxford Biomedica or Smith & Nephew: which is stronger?
- SN.L
Which is more profitable?
Smith & Nephew keeps more of each sale as profit: 10.1% against −23.2%.
- OXB.L
Which is growing its sales faster?
Oxford Biomedica is growing its sales faster: +9.00% over the past year, against +4.60%.
- SN.L
Which has borrowed less?
Smith & Nephew has borrowed less: its debt is 73.1% of what its shareholders own, against 273.1% for Oxford Biomedica.
- SN.L
Which costs less for the profit it is expected to make?
Smith & Nephew is expected to make a profit over the next year, where Oxford Biomedica is expected to make a loss.
Which pays more in dividends?
Smith & Nephew pays 2.55% a year in dividends for what a share costs, where Oxford Biomedica pays none.
- OXB.L
Which do analysts rate higher?
Analysts are warmer on Oxford Biomedica: Buy, against Hold for Smith & Nephew.
- SN.L
Which is in the stronger price trend?
Smith & Nephew's price is in the stronger trend: 1.4% above its 200-day average, against 5.2% below.
What each company does
OXB.LOxford Biomedica
Oxford Biomedica plc, a contract development and manufacturing organization, focuses on delivering therapies to patients worldwide.
Reports results on 25 March 2027
SN.LSmith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally.
Reports results on 1 March 2027
This comparison is just the starting point.
Discover opportunities, understand companies and compare investments in one place. See how StratDeck works
Keep researching
Where next
More comparisons
Free email
Up to speed in minutes, four times a week
Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.
Early access
Become a StratDeck founding user
Use StratDeck, tell us what's missing, and help decide what we build next.
100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.